<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01988506</url>
  </required_header>
  <id_info>
    <org_study_id>P130101</org_study_id>
    <secondary_id>2013-001232-22</secondary_id>
    <nct_id>NCT01988506</nct_id>
  </id_info>
  <brief_title>Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases</brief_title>
  <acronym>TRANSREG</acronym>
  <official_title>Induction of Regulatory t Cells by Low Dose IL2 in Autoimmune and Inflammatory Diseases: a Transnosographic Approach</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Iltoo Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      TRANSREG will assess the safety and biological efficacy of low-dose IL2 as a Treg inducer in
      a set of 14 autoimmune and auto-inflammatory diseases, with the aim to select diseases in
      which further therapeutic development will be performed. Extensive biological- and
      immune-monitoring pre- and post-IL2 will contribute (i) to define the common or distinct
      processes responsible for the breakdown of immunological tolerance in these pathologies and
      (ii) to discover potential biomarkers of the IL2 response.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Protocol: TRANSREG is a multicentric, uncontrolled, open-label study, comparing biological
      and clinical responses to the administration of low doses IL2 across 14 selected pathologies:
      rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, psoriasis,
      Behcet's disease, Wegener's granulomatosis, Takayasu's disease, Crohn's disease, ulcerative
      colitis, autoimmune hepatitis, sclerosing cholangitis, Gougerot-sjögren, Systemic Sclerosis
      and Idiopathic Thrombocytopenic Purpura. Methods: Each patient will receive 1MUI /day of IL2
      from Day-1 to Day-5 (the induction period), and then every 2 weeks (except systemic lupus
      erythematosus's patients will received every week) from Day-15 to Day-180 (the maintenance
      period). Patients will thereafter be followed up for 12 months (Day-181-Day-540). For each
      pathology, 6 patients will be included at Pitié-Salpêtrière, Cochin, Saint Antoine, Paul
      Brousse and Henri Mondor hospitals in Paris and Créteil, France. An interim analysis will be
      performed in each pathology group when the first six patients have received at least 3 months
      of treatment. In those pathology groups in which a Treg response will be documented, six
      additional patients will be included. In total, a minimum of 84 patients and up to 132
      patients will be enrolled in this study. Primary efficacy endpoint is the Treg response at
      Day-8 compared to baseline. Secondary efficacy endpoints are:- evolution of the Treg response
      during the maintenance period,- the changes in markers of inflammation - the clinical
      response, evaluated by means of global generic scales [Clinical Global Impression severity
      scale (CGI-sev) and Clinical Global Impression efficacy index (CGI-eff)] as well as specific
      clinical and biological evaluations for each disease, - the frequency of relapses, - the
      assessment of quality of life (scale EuroQL-5). Expected Results: TRANSREG will define which
      patients respond to IL2, whether per pathology or according to pre-treatment phenomics,
      allowing to guide further clinical development of low dose IL2 in autoimmune and
      auto-inflammatory diseases.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 6, 2014</start_date>
  <completion_date type="Anticipated">February 6, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 14, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentages of Tregs</measure>
    <time_frame>Day8</time_frame>
    <description>Change in Treg percentage (percentages of Tregs within the CD4+ lymphocytes) at Day-8 after administration of low-dose of IL2 compared to baseline (Day0)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentages of Tregs</measure>
    <time_frame>Day 15, 29, 85, 183, 240, 360 and 540</time_frame>
    <description>Changes in Treg percentage at Day 15, 29, 85, 183, 240, 360 and 540 compared to baseline (Day0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRP, CRP ulta sensible, PCT, Albumin, LDH, anemia</measure>
    <time_frame>Day 0, 1, 8, 15, 29, 85, 183, 240, 360 and 540</time_frame>
    <description>Changes in levels of inflammation markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of relapses</measure>
    <time_frame>up to Day540</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGI-sev and CGI-eff scales</measure>
    <time_frame>Day 85, 183, 240, 360 and 540</time_frame>
    <description>Change in the clinical global impression severity and efficacy scale (CGI-sev and scale, CGI-eff scales) at Day 85, 183, 240, 360 and 540 compared to baseline (Day1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQL-5 scale</measure>
    <time_frame>Day 183</time_frame>
    <description>Change in the quality of life (EuroQL-5 scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of clinical, biological or radiological criteria specific to each disease</measure>
    <time_frame>up to Day 540</time_frame>
    <description>Changes in disease-specific score and/or evolution of clinical, biological or radiological criteria specific to each disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Assessment</measure>
    <time_frame>up to Day 540</time_frame>
    <description>Safety Assessment all along the observation period (Day-1 to Day-240): Safety assessment will include vital signs, adverse events and concomitant medications collection as well as biology during the 6 months of the treatment period; .In addition, the evolution of the disease will be followed up to 1 year after IL2- treatment stop.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Ankylosing Spondylitis</condition>
  <condition>Systemic Lupus Erythematosus</condition>
  <condition>Psoriasis</condition>
  <condition>Behcet's Disease</condition>
  <condition>Wegener's Granulomatosis</condition>
  <condition>Takayasu's Disease</condition>
  <condition>Crohn's Disease</condition>
  <condition>Ulcerative Colitis</condition>
  <condition>Autoimmune Hepatitis</condition>
  <condition>Sclerosing Cholangitis</condition>
  <condition>Gougerot-sjögren</condition>
  <condition>Idiopathic Thrombocytopenic Purpura</condition>
  <condition>Systemic Sclerosis</condition>
  <arm_group>
    <arm_group_label>Interleukin 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Interleukin 2, 1MUI.= Proleukin®, RhIL-2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interleukin 2</intervention_name>
    <description>Induction period: repeated administration of low-dose IL-2 (1MUI/day, sc) during 5 consecutive days.Maintenance period: treatment with IL-2, 1MUI once every 15 days (except systemic lupus erythematosus's patients every 7 days) for 6 months</description>
    <arm_group_label>Interleukin 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt; 18 year

          -  male or female

          -  documented diagnosis of one AIID among the 14 diseases selected (following consensual
             specific criteria)

          -  stable or moderately active disease (except Lupus) under standard treatment (≥ 2
             months) at the time of inclusion (except Sclerosing Cholangitis, Gougerot-sjögren,
             Takayasu's Disease and Systemic Sclerosis)

          -  normal thyroid function (with or without treatment)

          -  effective contraception for more than two weeks at inclusion and negative beta HCG
             test for women of childbearing potential,

          -  affiliated to the social security system

          -  written informed consent form.

        Exclusion Criteria:

          -  known intolerance for IL2 (see SPC),

          -  administration of a non-authorized treatment and/or IV bolus of corticosteroids in the
             last 2 months,

          -  vaccination with live attenuated virus in the months preceding the inclusion or
             planned during the study

          -  other severe or progressive autoimmune/inflammatory pathology,

          -  low white blood cell count&lt;2000/mm3, lymphocytes &lt;600/mm3, platelets &lt;80 000/mm3,

          -  heart failure (≥ grade III NYHA), renal insufficiency (Cockcroft&lt; 60ml/mn except
             patients with lupus or Wegener's granulomatosis) or hepatic insufficiency
             (transaminases&gt; 5N except for patients with autoimmune hepatitis), or lung failure,

          -  significant abnormality in chest X-ray other than these linked to the diseases under
             investigation

          -  cancer or history of cancer cured for less than five years (except in situ carcinoma
             of the cervix or basocellular carcinoma)

          -  poor venous access not allowing repeated blood tests,

          -  restrictive diet or parenteral nutrition,

          -  surgery during the last 2 months or surgery planned during the study,

          -  participation in other biomedical research in the last 3 months or planned during the
             study.

          -  pregnant or lactating women,

          -  concomitant psychiatric disease or any other chronic illness or drug-abuse that could
             interfere with the ability to comply with the protocol or to give informed consent,

          -  positive HIV serology, active hepatitis B or EBV infection,

          -  patients under a measure of legal protection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David KLATZMANN, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David KLATZMANN, MD, PhD</last_name>
    <phone>+33(0) 1 42 17 74 61</phone>
    <email>david.klatzmann@upmc.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Roberta LORENZON, MD</last_name>
    <phone>+33(0) 1 42 17 74 61</phone>
    <email>rolorenzon@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service d' Hépato Gastro Entérologie - Hôpital SAINT-ANTOINE</name>
      <address>
        <city>Paris</city>
        <state>Ile De France</state>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier CHAZOUILLERES, MD, PhD</last_name>
      <phone>33 1.49.28.23.78</phone>
      <email>olivier.chazouilleres@sat.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier CHAZOUILLERES, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Gastro Entérologie - Hôpital SAINT-ANTOINE</name>
      <address>
        <city>Paris</city>
        <state>Ile De France</state>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent Beaugerie, MD, PhD</last_name>
      <phone>33 1 .49.28.31.71</phone>
      <email>laurent.beaugerie@sat.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Laurent BEAUGERIE, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Rhumatologie - Hôpital SAINT-ANTOINE</name>
      <address>
        <city>Paris</city>
        <state>Ile De France</state>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francis Berenbaum, MD, PhD</last_name>
      <phone>33 1 .49.28.25.20</phone>
      <email>francis.berenbaum@sat.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Francis. BERENBAUM, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CIC - Hôpital PITIE SALPETRIERE</name>
      <address>
        <city>Paris</city>
        <state>Ile De France</state>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberta LORENZON, MD</last_name>
      <phone>33 1 .42.17.85.33</phone>
      <email>roberta.lorenzo@upmc.fr</email>
    </contact>
    <investigator>
      <last_name>Nathalie Nicolas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Médecine Interne - Hôpital PITIE SALPETRIERE</name>
      <address>
        <city>Paris</city>
        <state>Ile De France</state>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrice CACOUB, MD, PhD</last_name>
      <phone>33 1 42.17.80.09</phone>
      <email>patrice.cacoub@psl.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Patrice CACOUB, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Rhumatologie - Hôpital PITIE SALPETRIERE</name>
      <address>
        <city>Paris</city>
        <state>Ile De France</state>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno FAUTREL, MD, PhD</last_name>
      <phone>33 1 .42.17.76.20</phone>
      <email>bruno.fautrel@psl.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Bruno FAUTREL, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Dermatologie - Hôpital COCHIN</name>
      <address>
        <city>Paris</city>
        <state>Ile De France</state>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salim Aractingi, MD, PhD</last_name>
      <phone>+ 33 1 56 01 64 62</phone>
      <email>selim.aractingi@gmail.com</email>
    </contact>
    <investigator>
      <last_name>ARACTINGI Selim, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hépato-Biliaire - Hôpital Paul Brousse</name>
      <address>
        <city>Villejuif</city>
        <state>Ile De France</state>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Charles DUCLOS-VALLEE, MD, PhD</last_name>
      <phone>33 1 45 59 64 33</phone>
      <email>jean-charles.duclos-vallee@pbr.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henri Mondor - Médecine Interne</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc MICHEL</last_name>
      <phone>33 1 49 81 29 04</phone>
      <email>Marc.michel2@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Marc MICHEL, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Médecine interne - Hôpital Saint-Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier FAIN, MD, PhD</last_name>
      <phone>33 1 49 28 21 04</phone>
      <email>olivier.fain@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier FAIN, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de médecine vasculaire - HEGP</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emmanuel MESSAS, MD, PhD</last_name>
      <phone>33 1 56 09 22 89</phone>
      <email>emmanuel.messas@egp.aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 7, 2013</study_first_submitted>
  <study_first_submitted_qc>November 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2013</study_first_posted>
  <last_update_submitted>January 10, 2018</last_update_submitted>
  <last_update_submitted_qc>January 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IL2,</keyword>
  <keyword>Interleukin 2,</keyword>
  <keyword>ILT101</keyword>
  <keyword>Proleukin®, RhIL-2</keyword>
  <keyword>Auto-immune disease</keyword>
  <keyword>Inflammatory disease</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Regulatory T cells,</keyword>
  <keyword>Treg</keyword>
  <keyword>Immunoregulation</keyword>
  <keyword>Immune tolerance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Psoriasis</mesh_term>
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
    <mesh_term>Purpura</mesh_term>
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic</mesh_term>
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Cholangitis, Sclerosing</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
    <mesh_term>Behcet Syndrome</mesh_term>
    <mesh_term>Granulomatosis with Polyangiitis</mesh_term>
    <mesh_term>Hepatitis, Autoimmune</mesh_term>
    <mesh_term>Takayasu Arteritis</mesh_term>
    <mesh_term>Aortic Arch Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interleukin-2</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

